prs-080
Biologicalexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02340572)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- HepcidinINHIBITOR
HAMP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- prs-080
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03325621 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2017 | FGK Clinical Research GmbH, Institute of Clinical and Experimental Medicine Nephrology Clinic Prague, Pieris Pharmaceuticals GmbH, Technical University of Munich |
| NCT02754167 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | FGK Clinical Research GmbH, Pieris Pharmaceuticals GmbH, Technical University of Munich |
| NCT02340572 | Phase 1 | Nov 1, 2014 | EUROCALIN Consortium, FGK Clinical Research GmbH, Nuvisan Pharma Services, Pieris Pharmaceuticals GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FGK Clinical Research GmbH | For profit | 3 | 0 | 2 | 2014 |
| Pieris Pharmaceuticals GmbH | For profit | 3 | 3 | 2 | 2014 |
| Technical University of Munich | Academic/Hospital | 2 | 0 | 1 | 2016 |
| EUROCALIN Consortium | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Institute of Clinical and Experimental Medicine Nephrology Clinic Prague | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Nuvisan Pharma Services | For profit | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1